Compare Innovative Industrial Properties Inc (IIPR) vs 10X Genomics Inc (TXG) Price & Performance

IIPR trades at $63.25, down 1.89% today, with a bullish technical signal from moving averages. The REIT shows strong profitability with 88.46% gross margins and 45.58% net income margin, though revenue declined to $266M in 2025. Recent news highlights successful debt refinancing and upcoming Q2 2026 earnings on August 3rd, with analyst consensus leaning Hold (54.55%).

The outlook remains cautious due to revenue declines and mixed earnings performance, but strong margins and recent capital structure improvements provide stability. Key risks include cannabis sector volatility and tenant credit quality, while the 9% dividend yield offers income appeal. Wall Street sentiment is neutral with balanced risk-reward.

TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.

The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.